Virtual Science AI
Andrew Donlon has extensive experience in the pharmaceutical industry, with a background in sales, marketing, and strategic planning. Andrew has worked in various roles at Gilead Sciences and GlaxoSmithKline, and currently serves as the Global Marketing Lead at Virtual Science. Andrew has been involved in launching innovative medications for diseases such as Hepatitis Delta Virus and HIV, and has a strong track record of successful market development and commercialization strategies. Andrew's expertise in driving global marketing initiatives and go-to-market strategies make him a valuable asset in the industry.
This person is not in any teams
Virtual Science AI
Virtual Science AI is reimagining how the Healthcare Industry generates external stakeholder insights. These insights are delivered via our unique and ground breaking artificial Intelligence platform, and are faster, clearer and more actionable. AI-driven analytics created through interactive data analysis, including sentiment analysis reports, ensure immediate actionable insights. The engagement of HCP's, patient experts, payers and other stakeholders provides end-to-end advisory services powered by our 24/7 engagement platform. Through asynchronized working, our clients determine key strategic insights that refine scientific and commercial messaging. The generation of these insights shapes the building of robust strategies that are co-created with HCP's, patients, payers and communities ensuring successful market dynamics and improving long-term patient care. The capitalisation of the company via Venture Capital and Health Tech funds is a reflection of the dynamic, exciting and innovative nature of our mission. Contact us now via our website, as we would love to demonstrate the significant benefits that our AI software platform will bring to your insight generation. http://www.virtualscienceai.com Take your insight generation to the next dimension